SCHEMBL2572273

SCHEMBL2572273

COCCc1cc(NCc2ccccc2)c([N+](=O)[O-])c(NCc2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.50
LMNA P02545 3/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 3/20 0.48
HTT P42858 3/20 0.48
ALDH1A1 P00352 1/20 0.48
NPSR1 Q6W5P4 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
BLM P54132 2/20 0.48
RECQL P46063 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
EGFR P00533 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 2/20 0.44
CRHBP P24387 2/20 0.44
KMT2A Q03164 2/20 0.44
CRHR2 Q13324 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2574381 0.91 MAPT (0.46) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2567876 0.85 MAPT (0.53) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2564349 0.83 LMNA (0.41) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2572361 0.82 MAPT (0.55) MAPTLMNAHPGDMAPK1HTT
SCHEMBL13407309 0.81 MAPT (0.59) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2572337 0.81 MAPT (0.53) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2573075 0.80 MAPT (0.55) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2573379 0.79 MAPT (0.51) MAPTLMNAHPGDMAPK1HTT
SCHEMBL12164325 0.77 MAPT (0.57) MAPTLMNAHPGDMAPK1HTT
SCHEMBL2572033 0.77 MAPT (0.49) MAPTLMNAHPGDMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987030-B1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LTD (GB) 2011-11-09 EP disclosed
US-7691877-B2 Pharmaceuticals PFIZER INC. (US) 2010-04-06 US disclosed
EP-1987030-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS Pfizer Limited (GB) 2008-11-05 EP disclosed
WO-2007093901-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LIMITED (GB) 2007-08-23 WO disclosed
US-20070197478-A1 NOVEL PHARMACEUTICALS PFIZER LIMITED 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197478-A1 NOVEL PHARMACEUTICALS TLR3, HAVCR2, TLR9 MAPT 4363/4885LMNA 4120/4885HPGD 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.